[go: up one dir, main page]

WO2008033432A3 - Immune modulation by chemically modified ribonucleosides and oligoribonucleotides - Google Patents

Immune modulation by chemically modified ribonucleosides and oligoribonucleotides Download PDF

Info

Publication number
WO2008033432A3
WO2008033432A3 PCT/US2007/019873 US2007019873W WO2008033432A3 WO 2008033432 A3 WO2008033432 A3 WO 2008033432A3 US 2007019873 W US2007019873 W US 2007019873W WO 2008033432 A3 WO2008033432 A3 WO 2008033432A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligoribonucleotides
chemically modified
immune modulation
modified ribonucleosides
ribonucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019873
Other languages
French (fr)
Other versions
WO2008033432A2 (en
Inventor
Jorg Vollmer
Stefan Bauer
Grayson B Lipford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group Inc
Original Assignee
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical GmbH, Coley Pharmaceutical Group Inc filed Critical Coley Pharmaceutical GmbH
Publication of WO2008033432A2 publication Critical patent/WO2008033432A2/en
Publication of WO2008033432A3 publication Critical patent/WO2008033432A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to modified oligoribonucleotides with immunomodulatory activity. The invention encompasses treatment of autoimmune and infectious diseases using the oligonucleotides of the invention.
PCT/US2007/019873 2006-09-12 2007-09-12 Immune modulation by chemically modified ribonucleosides and oligoribonucleotides Ceased WO2008033432A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84383806P 2006-09-12 2006-09-12
US60/843,838 2006-09-12

Publications (2)

Publication Number Publication Date
WO2008033432A2 WO2008033432A2 (en) 2008-03-20
WO2008033432A3 true WO2008033432A3 (en) 2008-11-06

Family

ID=39047781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019873 Ceased WO2008033432A2 (en) 2006-09-12 2007-09-12 Immune modulation by chemically modified ribonucleosides and oligoribonucleotides

Country Status (1)

Country Link
WO (1) WO2008033432A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NZ508927A (en) 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
DE60229422D1 (en) 2001-08-17 2008-11-27 Coley Pharm Gmbh COMBINATION MOTIF IMMUNOSTIMULATING OLIGONUCLEOTIDES WITH IMPROVED EFFECT
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
DK2241325T3 (en) 2002-10-29 2012-04-10 Coley Pharm Group Inc Use of CPG oligonucleotides to treat Hepatitis Cvirus infection
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
EP1728863A3 (en) 2003-10-30 2006-12-20 Coley Pharmaceutical GmbH C-class oligonucleotide analogs with enhanced immunostimulatory potency
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
BRPI0618857B1 (en) 2005-11-25 2022-07-19 Zoetis Belgium S.A ISOLATED RNA OLIGONUCLEOTIDE, AND METHOD TO NEGATIVELY REGULATE IMMUNOSUPPRESSANT CD4+ REGULATORY CELLS
CN101517082B (en) 2006-09-27 2014-01-22 科勒制药有限责任公司 Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
CN102481375B (en) 2009-05-27 2017-06-06 西莱克塔生物科技公司 Nanocarrier Processing Components with Different Release Rates
EA023897B1 (en) 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Compositions that induce t cell help
JP6324067B2 (en) 2010-05-26 2018-05-16 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Multivalent synthetic nanocarrier vaccine
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 substituted nucleotide analogs
EA201390660A1 (en) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. MODIFIED NICOTINE COMPOUNDS AND RELATED METHODS
WO2012138846A2 (en) * 2011-04-05 2012-10-11 The Regents Of The University Of California Method and compositions comprising small rna agonist and antagonists to modulate inflammation
KR20140050698A (en) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
KR20150127206A (en) 2013-03-14 2015-11-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Nanoparticle-based compositions
US9828641B2 (en) 2013-08-01 2017-11-28 The Regents Of The University Of California Systemic genotoxicity as blood marker for allergic inflammation
EP3556353A3 (en) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
EA201692512A1 (en) 2014-06-25 2017-07-31 Селекта Байосайенсиз, Инк. METHODS AND COMPOSITIONS FOR THE TREATMENT BY SYNTHETIC NANOSEMS AND INHIBITORS OF THE IMMUNE CONTROL POINT
US10538769B2 (en) 2015-09-04 2020-01-21 Oregon State University Renal selective inhibition of cytochrome P450 3A5
US12365714B2 (en) 2018-03-05 2025-07-22 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
WO2019207066A1 (en) * 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of sjögren's syndrome
CA3144902A1 (en) 2019-08-14 2022-01-19 Andreas Thess Rna combinations and compositions with decreased immunostimulatory properties
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20030232443A1 (en) * 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20030232443A1 (en) * 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression

Also Published As

Publication number Publication date
WO2008033432A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008033432A3 (en) Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
EP4435100A3 (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2004112687A3 (en) Antiviral acylguanidine compounds and methods
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2009011500A (en) Anti-mdl-1 antibodies.
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
WO2005079533A3 (en) Methods and compositions for mediating gene silencing
WO2012083048A3 (en) Anti-viral compounds
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
EP1954788A4 (en) Combustion catalyst carriers and methods of using the same
WO2009121948A3 (en) Single domain antibodies capable of modulating bace activity
WO2012083061A3 (en) Anti-viral compounds
WO2010011331A3 (en) Compositions and methods related to sirt1 function
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2012083058A3 (en) Anti-viral compounds
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2007130616A3 (en) Polyamides for treating human papilloma virus
WO2010052559A8 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
ZA200908525B (en) Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
WO2007011639A3 (en) Catalytic immunoglobulins
WO2007103584A3 (en) Polyamides for treating human papilloma virus
WO2010042633A3 (en) Naringenin complexes and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838130

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838130

Country of ref document: EP

Kind code of ref document: A2